Cx Precision Medicine
Cx Precision Medicine is dedicated to transforming the diagnosis and treatment of neurodegenerative disorders such as Alzheimer’s Dementia and Parkinson’s Disease through innovative blood tests and precision medicine technology. Their NeuroFirst™ tests enable earlier detection and targeted interventions, improving patient outcomes and reducing costs. The company combines proteomics and artificial intelligence to develop evidence-based, targeted diagnostic tools, aiming to change expectations in neurodegenerative disease management.
Industries
Nr. of Employees
small (1-50)
Cx Precision Medicine
Fort Worth, Texas, United States, North America
Products
Earlier-detection blood test for memory-related cognitive complaints (clinical diagnostic)
A blood-based diagnostic intended for adults 60+ to support primary care assessment of memory complaints by identifying individuals unlikely to have Alzheimer’s dementia and those needing further neurological evaluation.
Blood-based screening test for Parkinson’s disease (development)
A blood-based test under development intended to aid primary care identification of patients who should be further evaluated for Parkinson’s disease.
NeuroFirst™
NeuroFirst™ Memory is a simple blood test that helps primary care physicians distinguish Alzheimer's-related memory issues from other non-AD causes by ruling out Alzheimer's Dementia and some other dementias. It combines proteomics biomarkers with AI machine learning algorithms to analyze a large number of proteins in blood, providing a non-invasive diagnostic tool.
NeuroFirst™ Parkinson’s
A simple blood test that helps primary care physicians identify patients who should be further evaluated for Parkinson’s Disease by ruling out Parkinson’s in patients with neuromuscular concerns such as motor/gait issues or tremors.
Lewy Body Dementia Rule-Out
A diagnostic test in development by Cx Precision Medicine to rule out Lewy Body Dementia.
Earlier-detection blood test for memory-related cognitive complaints (clinical diagnostic)
A blood-based diagnostic intended for adults 60+ to support primary care assessment of memory complaints by identifying individuals unlikely to have Alzheimer’s dementia and those needing further neurological evaluation.
Blood-based screening test for Parkinson’s disease (development)
A blood-based test under development intended to aid primary care identification of patients who should be further evaluated for Parkinson’s disease.
NeuroFirst™
NeuroFirst™ Memory is a simple blood test that helps primary care physicians distinguish Alzheimer's-related memory issues from other non-AD causes by ruling out Alzheimer's Dementia and some other dementias. It combines proteomics biomarkers with AI machine learning algorithms to analyze a large number of proteins in blood, providing a non-invasive diagnostic tool.
NeuroFirst™ Parkinson’s
A simple blood test that helps primary care physicians identify patients who should be further evaluated for Parkinson’s Disease by ruling out Parkinson’s in patients with neuromuscular concerns such as motor/gait issues or tremors.
Lewy Body Dementia Rule-Out
A diagnostic test in development by Cx Precision Medicine to rule out Lewy Body Dementia.
Services
Design and participation in clinical validation studies and collaborations with academic partners to evaluate blood-based biomarker tests.
Analytical service consisting of algorithm development and application to large proteomic datasets to generate diagnostic classifications and signatures.
Design and participation in clinical validation studies and collaborations with academic partners to evaluate blood-based biomarker tests.
Analytical service consisting of algorithm development and application to large proteomic datasets to generate diagnostic classifications and signatures.
Expertise Areas
- Blood-based biomarker discovery and validation
- Proteomic biomarker signature development
- AI-driven diagnostic algorithm development
- Analytical assay validation across sample types and platforms
Key Technologies
- Proteomics (large-panel protein quantification)
- Machine learning / artificial intelligence for biomarker analysis
- Blood-based biomarker assays (serum/plasma)
- Multiplex protein measurement techniques